Qingqing Qin

Dr. Qingqing Qin


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
QWQin Wang
Qin Wang
QQQingqing Qin
Qingqing Qin
LWLiang Wenqiang
Liang Wenqiang
HGHaoran Guo
Haoran Guo
YDYang Diao
Yang Diao
XWXin Wang
Xin Wang
During the pathological process of spinal cord injury (SCI), ferroptosis is closely related to mitochondrial homeostasis. Following the occurrence of SCI, the interruption of local blood supply leads to mitochondrial damage within cells and a reduction in Adenosine triphosphate (ATP) production. This results in the loss of transmembrane ion gradients, causing an influx of Ca2+ into the cells, which in turn generates a significant amount of Reactive oxygen species (ROS) and reactive nitrogen species. This leads to severe mitochondrial dysfunction and an imbalance in mitochondrial homeostasis. Ferroptosis is a form of programmed cell death that differs from other types of apoptosis, as it is dependent on the accumulation of iron and lipid peroxides, along with their byproducts. The double bond structures in intracellular polyunsaturated fatty acids (PUFA) are particularly susceptible to attack by ROS, leading to the formation of lipid alkyl free radicals. This accumulation of lipid peroxides within the cells triggers ferroptosis. After SCI, the triggering of ferroptosis is closely associated with the “death triangle”—a core network that catalyzes cell death through the interaction of three factors: local iron overload, collapse of antioxidant defenses, and dysregulation of PUFA metabolism (where PUFA are susceptible to attack by reactive ROS leading to lipid peroxidation). These three elements interact to form a central network driving cell death. In the pathological cascade of SCI, mitochondria serve as both a major source of ROS and a primary target of their attack, playing a crucial role in the initiation and execution of cellular ferroptosis. Mitochondrial homeostasis imbalance is not only a key inducer of the “death triangle” (such as the intensification of lipid peroxidation by mitochondrial ROS), but is also reverse-regulated by the “death triangle” (such as the destruction of mitochondrial structure by lipid peroxidation products). Through the cascade reaction of this triangular network, mitochondrial homeostasis imbalance and the “death triangle” jointly drive the progression of secondary damage. This study aims to synthesize the mechanisms by which various therapeutic approaches mitigate SCI through targeted regulation of mitochondrial homeostasis and inhibition of ferroptosis. Unlike previous research, we integrate the bidirectional regulatory relationship between “mitochondrial homeostasis disruption” and “ferroptosis” in SCI, and emphasize their importance as a synergistic therapeutic target. We not only elaborate in detail how mitochondrial homeostasis—including biogenesis, dynamics, and mitophagy—modulates the initiation and execution of ferroptosis, but also summarize recent strategies that simultaneously target both processes to achieve neuroprotection and functional recovery. Furthermore, this review highlights the translational potential of various treatments in blocking the pathological cascade driven by oxidative stress and lipid peroxidation. These insights provide a novel theoretical framework and propose combinatory therapeutic approaches, thereby laying the groundwork for designing precise and effective comprehensive treatment strategies for SCI in clinical settings.

18 September 2026 in Medicine
Verified
Journal Article
Open access
JWJiantong Wei
Jiantong Wei
QQQingqing Qin
Qingqing Qin
HCHao Chen
Hao Chen
LWLiang Wenqiang
Liang Wenqiang
YWYaohua Wang
Yaohua Wang
This study aims to systematically assess the global burden of musculoskeletal (MSK) diseases caused by high body mass index (BMI) and to analyze its temporal trends and cross-national inequalities. Data were extracted from the Global Burden of Disease 2021. We quantified the temporal trends by calculating the estimated annual percentage change of the age-standardized DALYs rate (ASDR). Joinpoint regression analysis was used to identify the significant turning points in the ASDR. The cross-national inequality situation was evaluated using the sociodemographic index (SDI). The Bayesian Age-Period-Cohort model was constructed to predict the disease burden up to 2050. Over the past 30 years, the ASDR for MSK diseases attributable to high BMI increased substantially from 110.57 per 100,000 in 1990 to 155.33 per 100,000 in 2021. In 2021, the ASDR of MSK diseases attributable to high BMI was highest in areas with high SDI and lowest in areas with low SDI, and there was a clear positive association between the ASDR of MSK diseases attributable to high BMI and SDI levels. By sex and age, the burden of MSK disease attributable to high BMI is much higher in women than in men, and disability-adjusted life years cases of MSK disease attributable to high BMI peak in the 55 to 59 age group, globally. Cross-country inequality analysis showed that there were clear absolute and relative SDI-related inequalities in disability-adjusted life years of MSK disease attributable to high BMI in 204 countries and regions, with countries and regions with higher SDI bearing a disproportionate burden. In addition, the global burden of MSK disease attributable to high BMI is likely to increase further between 2022 and 2050. Since 1990, the global burden of MSK diseases attributable to high BMI has been clearly rising. The burden of MSK disease attributable to high BMI varies significantly across countries, regions, genders, and ages. Public health strategies that address obesity risk factors are critical to reducing the growing burden of MSK disease.